Supernus rises on FDA label expansion of ADHD therapy

May 02, 2022 6:32 AM ETSupernus Pharmaceuticals, Inc. (SUPN)By: Dulan Lokuwithana, SA News Editor


Devonyu/iStock via Getty Images

  • Supernus Pharmaceuticals (NASDAQ:SUPN), a pharma company focused on CNS disorders, is trading ~9% higher in the pre-market Monday after the firm announced that the U.S. Food and Drug Administration (FDA) expanded the indication for its ADHD

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.